Business Context and Reporting Period
Company: James Hardie Industries plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of October 2018
Filing Date: October 18, 2018
This filing serves as a notification of a change in substantial holding (Exhibit 99.1). The document does not contain operational results or financial statements for the period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing regarding a change in substantial holding and does not include financial performance data.
Material Changes
The primary material change disclosed in this filing is a Change in substantial holding, as referenced in Exhibit 99.1. No other material changes to operations or financial condition are detailed in the provided text.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes an extensive disclaimer regarding forward-looking statements. These statements cover future performance, capital expenditure projects, credit facility renewals, dividend payments, and share buy-backs.
Key Risks Identified:
- Liabilities related to prior manufacture of asbestos-containing products.
- Required contributions to the Asbestos Injuries Compensation Fund (AICF) and potential shortfalls.
- Currency exchange rate movements affecting asbestos liabilities.
- Compliance with tax laws and potential tax charges.
- Competition, product pricing, and product failures.
- Legal proceedings including environmental, asbestos, and consumer class actions.
- General economic conditions, housing market recovery, and interest rates.
- Integration of Fermacell into the business.
Investor Verification Checklist
- Review Exhibit 99.1 (Change in substantial holding) to identify the specific shareholder and the nature of the change.
- Verify the current status of the Asbestos Injuries Compensation Fund (AICF) and recent contribution requirements.
- Check the most recent Form 20-F for detailed financial metrics, as this 6-K does not contain them.
- Monitor updates on the Fermacell integration and associated capital expenditure projects.
- Assess current currency exchange rates impacting the company's international operations and liabilities.